<DOC>
	<DOCNO>NCT00762892</DOCNO>
	<brief_summary>This pilot evaluate two regimen treat HIV infect patient n't treatment . HIV/AIDS patient may increase risk myocardial infarction antiretroviral therapy use may contribute . We evaluate virological , immunological cardiovascular effect two HIV treatment regimen .</brief_summary>
	<brief_title>Raltegravir vs. Atazanavir Combination With Truvada速 Treatment Antiretroviral na誰ve HIV Infected Patients</brief_title>
	<detailed_description>We check blood study use evaluate HIV patient response therapy include CD4 count HIV viral load test . We check routine safety lab do HIV patient also check homocysteine level creatine kinase level . We evaluate homocysteine IL6 level baseline , week 48 , week 96 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Patients must HIV1 positive na誰ve HIV therapy . Patients must plan participate available trial 96week study period . Patients follow Thomas Street Clinic . Patients must 18 year old . Patients must pregnant plan become pregnant 96week study period . Patients proton pump inhibitor . Patients undergoing treatment active tuberculosis . Renal Insufficiency creatinine clearance &lt; 50 ml/min/1.73 m2 MDRD GFR calculation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Raltegravir</keyword>
	<keyword>Integrase inhibitor</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Naive patient</keyword>
	<keyword>HIV disease</keyword>
	<keyword>Lipids</keyword>
	<keyword>Treatment Na誰ve</keyword>
</DOC>